Novartis: EU regulator backs rare blood diseases drug.
(CercleFinance.com) - Europe's drugs regulator gave its backing for marketing approval to be granted for Novartis' Rydapt for newly diagnosed FLT3-mutated acute myeloid leukaemia and three types of advanced systemic mastocytosis.
If approved, Rydapt will be the first targeted treatment available in the European Union for newly diagnosed FLT3 mutation-positive acute myeloid leukaemia patients and advanced systemic mastocytosis patients.
Advanced systemic mastocytosis is a rare and aggressive cancer of the blood and bone marrow. Advanced systemic mastocytosis is a rare blood disorder characterised by uncontrolled growth and accumulation of mast cells—the mediators of allergic responses.
The opinion follows a recent US FDA approval of Rydapt in April.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
If approved, Rydapt will be the first targeted treatment available in the European Union for newly diagnosed FLT3 mutation-positive acute myeloid leukaemia patients and advanced systemic mastocytosis patients.
Advanced systemic mastocytosis is a rare and aggressive cancer of the blood and bone marrow. Advanced systemic mastocytosis is a rare blood disorder characterised by uncontrolled growth and accumulation of mast cells—the mediators of allergic responses.
The opinion follows a recent US FDA approval of Rydapt in April.
Copyright (c) 2017 CercleFinance.com. All rights reserved.